Quality

FDA is aligning its QSR (21 CFR 820) with ISO 13485:2016

blogs, Markets, Medical Devices, North America, Quality, Regulatory, Resource Center, United States / By

By 2020, the Food and Drug Administration (FDA) is planning to change its quality system requirements for medical device manufacturers stipulated in 21 CFR 820 by ISO 13485 :2016. This decision was taken as more and more regulators are looking toward adopting globally harmonized requirements that utilize regulations as well as standards, such as ISO …

FDA is aligning its QSR (21 CFR 820) with ISO 13485:2016 Read More

A review of the changes in ISO 13485

Quality, Regulatory, Resource Center / By

On February 25, 2016, the International Organization for Standardization (ISO) published its revisions to ISO 13485 replacing the previous version from 2003. This is the global standard for medical device quality management systems (QMS). Over the next three years, ISO 13485:2003 and ISO 13485:2016 will coexist, allowing manufacturers, accreditation/certification bodies and regulators time to transition …

A review of the changes in ISO 13485 Read More

Useful Links

Resources

What our Clients say about Us

Thank you GRP team for registering our DMF in china. Your helped us achieve a big milestone for our company. The support and the commitment of your regulatory team have exceeded our expectations and made it easier for us to communicate with NMPA the Chinese authority. All the best !
Director of Regulatory Affairs Officer- CMC- A Large European Pharmaceutical Company based in Switzerland
We have been working with Global Regulatory Partners for 5 years and we consider them as our real partner and not as a consulting company, they had submitted 3 INDs for us with FDA successfully . The GRP team performs all IND amendments and annual reporting to FDA, we don’t have to worry about not being in compliance with FDA requirements at all.
CEO of Medium Size American Pharmaceutical Company operating in Nanotechnology based in USA
After submitting our drug application to NPMA ( Chinese FDA) , the Chinese agency requested us to conduct a local clinical study. Finding the qualified CRO for the study management in china was very challenging process because of the language barrier and the lack of understanding of GCP and ICH requirements. We finally found Global Regulatory Partners, that has a local team of professionals in regulatory and clinical affairs in china who not only conducted successfully our clinical study in china, but also helped us to understand the Chinese regulations related to our product.
CMO of Large European Pharmaceutical Company based in France and Operating in Radiopharmaceuticals
I am very impressed on how quickly Global Regulatory Affairs team was able to prepare and organize a face to face consultation meeting for our company with Anvisa in Brazil, The meeting was successful and helped us to validate and conform the regulatory strategy of our device registration in Brazil.
VP of Global Regulatory Affairs, American Based Medical device Company

Copyright ©2019 Global Regulatory Partners

Scroll to Top

Contact